$HRTX alerted yesterday, Heron Therapeutics, Inc
Post# of 22759
(Total Views: 159)
Posted On: 01/10/2017 9:19:45 AM
$HRTX alerted yesterday,
Heron Therapeutics, Inc. to Post FY2016 Earnings of ($4.35) Per Share, Leerink Swann Forecasts (HRTX)
Posted by Wayne Landers on Jan 10th, 2017 // No Comments
Heron Therapeutics logoHeron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Leerink Swann issued their FY2016 earnings per share estimates for shares of Heron Therapeutics in a research note issued on Wednesday. Leerink Swann analyst J. Gerberry expects that the brokerage will earn ($4.35) per share for the year. Leerink Swann has a “Buy” rating and a $21.00 price objective on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($1.01) EPS, Q1 2017 earnings at ($0.86) EPS, Q2 2017 earnings at ($1.04) EPS, Q3 2017 earnings at ($0.80) EPS, Q4 2017 earnings at ($0.72) EPS, FY2017 earnings at ($3.38) EPS, FY2018 earnings at ($2.44) EPS, FY2019 earnings at ($0.75) EPS and FY2020 earnings at $1.26 EPS.
Other equities analysts have also recently issued reports about the company. Cowen and Company restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research report on Friday. Jefferies Group set a $29.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 5th. Cantor Fitzgerald restated a “buy” rating and set a $34.00 target price on shares of Heron Therapeutics in a research report on Thursday, November 10th. JMP Securities restated a “buy” rating on shares of Heron Therapeutics in a research report on Wednesday, November 9th. Finally, Aegis started coverage on Heron Therapeutics in a research report on Wednesday, October 26th. They set a “buy” rating and a $41.00 target price for the company. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $37.75.
Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)
Heron Therapeutics (NASDAQ:HRTX) opened at 13.50 on Monday. Heron Therapeutics has a 52-week low of $12.30 and a 52-week high of $25.84. The firm has a 50-day moving average price of $14.54 and a 200 day moving average price of $17.06.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.07.
Large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock worth $139,937,000 after buying an additional 229,182 shares during the period. FMR LLC raised its stake in Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock worth $99,156,000 after buying an additional 63,968 shares during the period. Janus Capital Management LLC raised its stake in Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock worth $72,450,000 after buying an additional 516,166 shares during the period. Baker BROS. Advisors LP bought a new stake in Heron Therapeutics during the third quarter worth $49,230,000. Finally, Vanguard Group Inc. raised its stake in Heron Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,215,343 shares of the biotechnology company’s stock worth $21,937,000 after buying an additional 58,039 shares during the period.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
5 Day Chart for NASDAQ:HRTX
Heron Therapeutics, Inc. to Post FY2016 Earnings of ($4.35) Per Share, Leerink Swann Forecasts (HRTX)
Posted by Wayne Landers on Jan 10th, 2017 // No Comments
Heron Therapeutics logoHeron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Leerink Swann issued their FY2016 earnings per share estimates for shares of Heron Therapeutics in a research note issued on Wednesday. Leerink Swann analyst J. Gerberry expects that the brokerage will earn ($4.35) per share for the year. Leerink Swann has a “Buy” rating and a $21.00 price objective on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($1.01) EPS, Q1 2017 earnings at ($0.86) EPS, Q2 2017 earnings at ($1.04) EPS, Q3 2017 earnings at ($0.80) EPS, Q4 2017 earnings at ($0.72) EPS, FY2017 earnings at ($3.38) EPS, FY2018 earnings at ($2.44) EPS, FY2019 earnings at ($0.75) EPS and FY2020 earnings at $1.26 EPS.
Other equities analysts have also recently issued reports about the company. Cowen and Company restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research report on Friday. Jefferies Group set a $29.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 5th. Cantor Fitzgerald restated a “buy” rating and set a $34.00 target price on shares of Heron Therapeutics in a research report on Thursday, November 10th. JMP Securities restated a “buy” rating on shares of Heron Therapeutics in a research report on Wednesday, November 9th. Finally, Aegis started coverage on Heron Therapeutics in a research report on Wednesday, October 26th. They set a “buy” rating and a $41.00 target price for the company. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $37.75.
Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)
Heron Therapeutics (NASDAQ:HRTX) opened at 13.50 on Monday. Heron Therapeutics has a 52-week low of $12.30 and a 52-week high of $25.84. The firm has a 50-day moving average price of $14.54 and a 200 day moving average price of $17.06.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.07.
Large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock worth $139,937,000 after buying an additional 229,182 shares during the period. FMR LLC raised its stake in Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock worth $99,156,000 after buying an additional 63,968 shares during the period. Janus Capital Management LLC raised its stake in Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock worth $72,450,000 after buying an additional 516,166 shares during the period. Baker BROS. Advisors LP bought a new stake in Heron Therapeutics during the third quarter worth $49,230,000. Finally, Vanguard Group Inc. raised its stake in Heron Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,215,343 shares of the biotechnology company’s stock worth $21,937,000 after buying an additional 58,039 shares during the period.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
5 Day Chart for NASDAQ:HRTX
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼